ARDX
NASDAQ
$5.09
Ardelyx Inc (ARDX)
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $16.30 (+220.24%)
Market Cap
$1.31B
Revenue 5Y CAGR
+101.30%
Free Cash Flow Yield
-2.86%
Beta (5Y)
0.79
Price Chart
Valuation
Market Cap$1.31B
Forward P/E40.65
P/S2.98
P/B8.58
Profitability
Total Revenue (TTM)$428M
Gross Profit (TTM)$319M
EBITDA-$34M
Profit Margin-39.8%
Operating Margin-34.7%
EPS-$0.24
Financial Health
Debt-to-Equity136.9%
Free Cash Flow Yield-2.86%
Growth & Risk
EPS 5Y CAGR-26.76%
Revenue 5Y CAGR+101.30%
FCF 5Y CAGR-18.10%
Beta (5Y)0.79
Sharpe Ratio0.43